817 related articles for article (PubMed ID: 24843055)
21. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
22. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
[TBL] [Abstract][Full Text] [Related]
23. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
[TBL] [Abstract][Full Text] [Related]
24. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
25. Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
Heinen S; Pluthero FG; van Eimeren VF; Quaggin SE; Licht C
Mol Immunol; 2013 May; 54(1):84-8. PubMed ID: 23220071
[TBL] [Abstract][Full Text] [Related]
26. [A case of atypical hemolytic uremic syndrome successfully weaned from plasma exchange by treatment with eculizumab].
Nagata A; Ohara A; Wakasugi D; Natori C; Ito S; Taguchi K; Fukami K; Okuda S
Nihon Jinzo Gakkai Shi; 2014; 56(5):606-11. PubMed ID: 25130033
[TBL] [Abstract][Full Text] [Related]
27. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
28. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Vondrák K; Seeman T
Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
[TBL] [Abstract][Full Text] [Related]
29. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
30. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
Carr R; Cataland SR
Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
[No Abstract] [Full Text] [Related]
31. Successful treatment of DEAP-HUS with eculizumab.
Noone D; Waters A; Pluthero FG; Geary DF; Kirschfink M; Zipfel PF; Licht C
Pediatr Nephrol; 2014 May; 29(5):841-51. PubMed ID: 24249282
[TBL] [Abstract][Full Text] [Related]
32. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
[TBL] [Abstract][Full Text] [Related]
33. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Noris M; Remuzzi G
Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
[TBL] [Abstract][Full Text] [Related]
34. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
36. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
37. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.
Dorresteijn EM; van de Kar NC; Cransberg K
Pediatr Nephrol; 2012 Jul; 27(7):1193-5. PubMed ID: 22399074
[TBL] [Abstract][Full Text] [Related]
39. Atypical hemolytic uremic syndrome.
Kavanagh D; Goodship TH
Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
[TBL] [Abstract][Full Text] [Related]
40. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
Laurence J
Clin Adv Hematol Oncol; 2020 Apr; 18(4):221-230. PubMed ID: 32628650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]